What value health?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The objective of this article was to review the methods used to obtain quality-of-life (utility) weights reported in assessments carried out for the National Institute for Health and Clinical Excellence (NICE).
The design of the review was a cross-sectional survey. Health technology assessment (HTA) reports published on the NICE website up to May 2003 were reviewed. Data were extracted on the following: the approach to utility estimation (direct or indirect), how health states were described for indirect estimation, valuation techniques used (standard gamble [SG], time trade-off [TTO], visual analogue scale [VAS], etc.), whether uncertainty in utility estimates was explored in cost-utility analyses, and whether utility values were identified as a priority for further research by assessment authors.
Fifty-six assessments were reviewed, of which 28 reported 45 cost-utility analyses. There was striking variation in the values used to describe different health states. Data from patients were used in 15 (33%) analyses, from the general public in 10 (22%) and from clinicians in 4 (9%). In 16 (36%) cases, the source for utility estimates was unclear. Health states were described using a range of generic and disease-specific measures, although the EQ-5D was used most frequently. In 25 analyses (56%), the valuation technique used was not reported. TTO was used in 11 (24%), SG in 3 (7%), magnitude estimation in 5 (11%) and VAS in 1 (2%). Sensitivity analyses based on utility values were reported in 25 cases (56%), more commonly in reports of analyses carried out by independent teams than technology sponsors although this may be subject to reporting bias. Further research into quality of life was recommended in 17 (61%) of the 28 assessment reports that contained at least one cost-utility analysis.
Greater transparency and consistency are required in reporting the methods used to obtain quality-of-life weights in cost-utility analyses, and better sources of data are required. Methodological variation results in important differences in values. Therefore, caution must be exercised when comparing the results of different cost-utility analyses.
- Guide to the methods of technology appraisal. NICE, London
- Warren, E., Weatherley-Jones, E., Chilcott, J. (2002) The clinical and cost-effectiveness of long-acting insulin analogue, insulin glargine. School of Health and Related Research, Sheffield
- Kaltenthaler, E., Shackley, P., Stevens, K. (2002) Computerised cognitive behaviour therapy for depression and anxiety. ScHARR Rapid Reviews Group, School of Health and Related Research, University of Sheffield, Sheffield
- Vale, L., Wyness, L., McCormack, K. (2001) Systematic review of the effectiveness and cost effectiveness of metal on metal hip resurfacing for treatment of hip disease. Health Services Research Unit, University of Aberdeen, Aberdeen
- Jobanputra, P., Barton, P., Bryan, S. (2001) The clinical effectiveness and cost-effectiveness of new drug treatments for rheumatoid arthritis: etanercept and infliximab. West Midlands Development and Evaluation Service, University of Birmingham, Birmingham
- Stewart, A., Sandercock, J., Bryan, S. (2000) The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease. West Midlands Development and Evaluation Service, Birmingham
- Turner, D., Wailoo, A., Nicholson, K. (2002) Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. University of Leicester/ScHARR, University of Sheffield, Leicester
- Clark, W., Burls, A., Song, F. (2001) Infliximab for the treatment of Crohn’s disease. West Midlands Development and Evaluation Service, University of Birmingham, Birmingham
- Thomas, S., Prince, A., Humphries, C. (2000) Assessment of interferon-beta and glatiramer for the treatment of multiple sclerosis. Regional Drug and Therapeutics Centre, Newcastle upon Tyne
- Bagnall, A.-M., Jones, L., Ginnelly, L. (2001) A rapid and systematic review of atypical antipsychotics in schizophrenia. NHS Centre for Reviews and Dissemination, York
- Wake, B., Bryan, S., Barton, P. (2001) Rituximab as third line treatment for refractory or recurrent stage III or IV follicular non-Hodgkin’s lymphoma. Department of Public Health and Epidemiology, University of Birmingham, Birmingham
- Lloyd, J. M., Hummel, S., Bansback, N. (2001) A review of the evidence for the clinical and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. The University of Sheffield School of Health and Related Research, Sheffield
- Shepherd, J., Waugh, N., Hewitson, P. (2000) Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C. Wessex Institute for Health Research & Development, Southampton
- Cody, J., Wyness, L., Wallace, S. (2002) Systematic review of the clinical effectiveness and cost-effectiveness of tension-free vaginal tape (TVT) for treatment of urinary stress incontinence. Health Services Research Unit, Aberdeen
- Kind, P., Hardman, G., Macran, S. (1999) UK population norms for EQ-5D [CHE discussion paper 172]. University of York, York
- Cummins, C., Connock, M., Fry-Smith, A. (2001) A rapid review of new drug treatments for juvenile idiopathic arthritis: etanercept. West Midlands Development and Evaluation Service, University of Birmingham, Birmingham
- Dinnes, J., Cave, C., Hunag, S. (2000) The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma. Wessex Institute for Health Research and Development, University of Southampton, Southampton
- Parkes, J., Bryant, J., Milne, R. (2000) Arrhythmias: implantable cardioverter defibrillators. National Coordinating Centre for Health Technology Assessments (NCCHTA), University of Southampton, Southampton
- Rosser, R., Cottee, M., Rabin, R. Index of health related quality of life. In: Hopkins, A. eds. (1992) Measures of the quality of life and the uses to which such measures may be put.
- O’Meara, S., Riemsma, R., Shirran, L. (2000) A systematic review of the clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity. NHS Centre for Reviews and Dissemination, University of York, York
- Brazier, J., Usherwood, T., Harper, R. (1998) Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 51: pp. 1115-28 CrossRef
- Deverill, M., Brazier, J., Green, C. (1998) The use of QALY and non-QALY measures of health-related quality of life. Pharmacoeconomics 13: pp. 411-20 CrossRef
- Hawthorne, G. (2000) The effect of different methods of collecting data: mail, telephone and filter data collection issues in utility measurement. Quality 12: pp. 1081-8
- Brooks, R. (1996) EuroQol: the current state of play. Health Policy 37: pp. 53-72 CrossRef
- Brazier, J., Deverill, M., Green, C. (1999) A review of the use of health status measures in economic evaluation. Health Technol Assess 3: pp. i-iv
- Burls A, Clark W, Stewart T, et al. Zanamivir for the treatment of influenza in adults. Birmingham: West Midlands Development and Evaluation Service, University of Birmingham, 2000 Jun 30
- Dolan, P., Gudex, C., Kind, P. (1996) The time trade-off method: results from a general population study. Health Econ 5: pp. 141-54 CrossRef
- Ubel, P.A., Loewenstein, G., Jepson, C. (2003) Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public. Qual Life Res 12: pp. 599-607 CrossRef
- Boland, A., Bagust, A., Hill, R. (2002) Early thrombolysis for the treatment of acute myocardial infarction. Liverpool Reviews and Implementation Group, Liverpool
- The, N. I. f. C. E. (2000) The clinical effectiveness and cost effectiveness of celecoxib, rofecoxib, meloxicam and etodolac (COX-II inhibitors) for rheumatoid arthritis and osteoarthritis. NICE, London
- Gold, M.R., Siegel, J.E., Russell, L.B. (1996) Cost-effectiveness in health and medicine. Oxford University Press, Oxford
- Dolan, P. (1998) Valuing health-related quality of life: issues and controversies. Pharmacoeconomics 15: pp. 119-27 CrossRef
- Rosser, R., Kind, P. (1978) A scale of valuations of states of illness: is there a social consensus?. Int J Epidemiol 7: pp. 347-58 CrossRef
- Neumann, P.J., Zinner, D.E., Wright, J.C. (1997) Are methods for estimating QALYs in cost-effectiveness analyses improving?. Med Decis Making 17: pp. 402-8 CrossRef
- Drummond, M., O’Brien, B., Stoddart, G. (1997) Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford
- Stalmeier, P.F.M., Goldstein, M.K., Holmes, A.M. (2001) What should be reported in a methods section on utility assessment?. Med Decis Making 21: pp. 200-7
- What value health?
Applied Health Economics and Health Policy
Volume 4, Issue 4 , pp 219-228
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Exeter and Plymouth, Exeter, England
- 4. Dean Clarke House, Peninsula Technology Assessment Group, Southernhay East, Exeter, EX1 1PQ, UK
- 2. National Coordinating Centre for Health Technology Assessment, University of Southampton, Southampton, England
- 3. Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, England